Giulia Marvaso: SBRT with and without ADT for hormone sensitive oligorecurrent prostate cancer
Giulia Marvaso, Assistant Professor at the University of Milan, posted on X about recent paper she and colleagues co-authored, titled “ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial” published on The Lancet Oncology.
Authors: Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, Maria Giulia Vincini, Chiara Lorubbio, Sara Gandini, Cristiana Fodor, Sofia Netti, Dario Zerini, Stefano Luzzago, Francesco Alessandro Mistretta, Konstantinos Venetis, Giulia Cursano, Tiziana Burla, Federica Cattani.
“RADIOSA full paper is finally out! Read our publication now online on The Lancet Oncology! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023